By Dr Jonathan Shurlock, edited by Dr. Ahmed El-Medany At TCT 2022 in the late-breaking clinical science session Dr Daniel Jones presented the findings of…
View More What is the role of CTCA prior to angiography in patients with previous CABG?
Category: News
The PROTECTED TAVR trial – what do the findings show?
By Dr Jonathan Shurlock, edited by Dr. Ahmed El-Medany Since its findings were presented at TCT 2022 the results of the PROTECTED TAVR trial have…
View More The PROTECTED TAVR trial – what do the findings show?
Is there a relationship between artificial sweetener consumption and cardiovascular disease?
By Dr. Jonathan Shurlock, edited by Dr. Ahmed El-Medany A large group led by PhD candidate Charlotte Debras have published their findings from the NutriNet-Santé…
View More Is there a relationship between artificial sweetener consumption and cardiovascular disease?
Fewer than 1-in-10 “statin-related” muscle pains are caused by statins
By Dr. Timothy Swinn, edited by Dr. Ahmed El-Medany A recent meta-analysis published in the Lancet[1] has concluded that fewer than 1 in 15 muscle…
View More Fewer than 1-in-10 “statin-related” muscle pains are caused by statins
Aspirin or P2Y12 inhibitor for coronary artery disease?
By Dr. Jonathan Shurlock, edited by Dr. Ahmed El-Medany Professor Marco Valgimigli presented the findings of the PANTHER analysis at the 2022 ESC congress. Currently…
View More Aspirin or P2Y12 inhibitor for coronary artery disease?
AVDOR: The resurrection of acetazolamide
By Dr. Aswin Babu, edited by Dr. Ahmed El-Medany At the most recent European Society of Cardiology (ESC) congress, the results of the AVDOR (Acetazolamide…
View More AVDOR: The resurrection of acetazolamide
DELIVER trial: Dapagliflozin reduces hospitalisation or cardiovascular death in patients with HFpEF and HFmrEF
By Dr. Timothy Swinn, edited by Dr. Ahmed El-Medany Recent evidence from the DELIVER trial[1], published in the New England Journal of Medicine and presented…
View More DELIVER trial: Dapagliflozin reduces hospitalisation or cardiovascular death in patients with HFpEF and HFmrEF
REVIVED-BCIS2: Cardiologists’ reactions around the Globe
Collated by Dr. Oliver Jones, edited by Dr. Ahmed El-Medany The bombshell results of REVIVED-BCIS landed this week at ESC 2022. BCS Heartbeat has reactions…
View More REVIVED-BCIS2: Cardiologists’ reactions around the Globe
SECURE Polypill trial: New life for an old idea
By Dr. Oliver Jones, edited by Dr. Ahmed El-Medany Key points: A polypill containing aspirin, ramipril, and atorvastatin was effective in reducing a composite of…
View More SECURE Polypill trial: New life for an old idea
PCI no better than OMT in severe Ischaemic Cardiomyopathy: REVIVED-BCIS2
By Dr. Ahmed El-Medany Key points: PCI does not reduce all-cause mortality or heart failure hospitilisation ins patients with severe LVSD and extensive CAD, and…
View More PCI no better than OMT in severe Ischaemic Cardiomyopathy: REVIVED-BCIS2